CN107875197A - A kind of composition and its production and use - Google Patents
A kind of composition and its production and use Download PDFInfo
- Publication number
- CN107875197A CN107875197A CN201610877072.3A CN201610877072A CN107875197A CN 107875197 A CN107875197 A CN 107875197A CN 201610877072 A CN201610877072 A CN 201610877072A CN 107875197 A CN107875197 A CN 107875197A
- Authority
- CN
- China
- Prior art keywords
- plant material
- composition
- preparation
- cream
- decocting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 238000004519 manufacturing process Methods 0.000 title abstract description 3
- 239000000463 material Substances 0.000 claims abstract description 47
- 239000006071 cream Substances 0.000 claims abstract description 45
- 241000196324 Embryophyta Species 0.000 claims abstract description 40
- 239000007788 liquid Substances 0.000 claims abstract description 35
- 241000894006 Bacteria Species 0.000 claims abstract description 29
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- 240000002505 Pogostemon cablin Species 0.000 claims abstract description 18
- 235000011751 Pogostemon cablin Nutrition 0.000 claims abstract description 17
- 201000006549 dyspepsia Diseases 0.000 claims abstract description 15
- 244000223014 Syzygium aromaticum Species 0.000 claims abstract description 13
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims abstract description 11
- 230000033228 biological regulation Effects 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 239000007787 solid Substances 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 21
- 235000013305 food Nutrition 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 21
- 239000002994 raw material Substances 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- 210000002784 stomach Anatomy 0.000 description 19
- 210000000214 mouth Anatomy 0.000 description 16
- 210000000952 spleen Anatomy 0.000 description 15
- 239000000243 solution Substances 0.000 description 11
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 10
- 229940012189 methyl orange Drugs 0.000 description 10
- 206010006326 Breath odour Diseases 0.000 description 9
- 208000032139 Halitosis Diseases 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 9
- 241001529821 Agastache Species 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 241000605986 Fusobacterium nucleatum Species 0.000 description 6
- 241000605862 Porphyromonas gingivalis Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 241000219061 Rheum Species 0.000 description 5
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000008673 vomiting Effects 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical class [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000030136 gastric emptying Effects 0.000 description 4
- 210000004051 gastric juice Anatomy 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000006072 paste Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- -1 sulphur compound Chemical class 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102400000921 Gastrin Human genes 0.000 description 2
- 108010052343 Gastrins Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- LJSQFQKUNVCTIA-UHFFFAOYSA-N diethyl sulfide Chemical compound CCSCC LJSQFQKUNVCTIA-UHFFFAOYSA-N 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 230000007661 gastrointestinal function Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- STZCRXQWRGQSJD-UHFFFAOYSA-M sodium;4-[[4-(dimethylamino)phenyl]diazenyl]benzenesulfonate Chemical compound [Na+].C1=CC(N(C)C)=CC=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-UHFFFAOYSA-M 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- BHNHHSOHWZKFOX-UHFFFAOYSA-N 2-methyl-1H-indole Chemical compound C1=CC=C2NC(C)=CC2=C1 BHNHHSOHWZKFOX-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 206010059186 Early satiety Diseases 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 206010016326 Feeling cold Diseases 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000027109 Headache disease Diseases 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000010804 Maranta arundinacea Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241001135221 Prevotella intermedia Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 235000008081 Rheum officinale Nutrition 0.000 description 1
- 240000004980 Rheum officinale Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 241001062472 Stokellia anisodon Species 0.000 description 1
- 206010042135 Stomatitis necrotising Diseases 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 244000145580 Thalia geniculata Species 0.000 description 1
- 235000012419 Thalia geniculata Nutrition 0.000 description 1
- 241000589892 Treponema denticola Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- KPQJOKRSYYJJEL-VLQRKCJKSA-K [Na+].[Na+].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C([O-])=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O Chemical compound [Na+].[Na+].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C([O-])=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O KPQJOKRSYYJJEL-VLQRKCJKSA-K 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 235000019525 fullness Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008125 glucin Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 244000000053 intestinal parasite Species 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000036445 liquid secretion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 201000008585 noma Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of composition and its production and use.Wherein, the active ingredient of composition combines from following plant material, and plant material combination includes the plant material of following parts by weight：1~10 part of cloves, 1~10 part of Pogostemon cablin.The preparation method of composition includes：Plant material will be weighed in proportion and mixed, boiled with decocting and collect decocting liquid；Decocting liquid is concentrated under reduced pressure in 60~80 DEG C, collects 1.20~1.50g/mL of solid content stream cream；Stream cream is prepared into preparation.Composition disclosed by the invention can provide regulation indigestion, suppress the effect of oral bacteria grows and then improves oral peculiar smell, have the characteristics that raw material is simple, have no toxic side effect, preparation method is simple, cost is cheap, applied widely.
Description
Technical field
The present invention provides a kind of composition, said composition can provide regulation indigestion, suppress oral bacteria grow into
And the effect of improving oral peculiar smell, present invention also offers the preparation method of said composition and purposes.
Background technology
Indigestion refers to one group of disease for showing as upper abdomen pain or burn feeling, postprandial Abdeminal pain and early full sense
Group, can be divided into Organic dyspepsia and functional digestive not with poor appetite, belch, nausea or vomiting etc. from the cause of disease
Good, its pathogenesis not yet illustrates completely, and its pathophysiological basis mainly includes following several respects：
(1) dyskinesia：Patient's proximal gastric adaptability diastolic function is damaged, and compliance declines, and causes in postprandial stomach
Food abnormal distribution, cause post-prandial fullness, early satiety etc.；
(2) visceral hypersensitivity：Patient stimulates dilatation of the stomach the order of severity for producing sense of discomfort apparently higher than normal healthy controls
Person；
(3) gastric acid secretion：Although patient base's gastric acid secretion, in normal range (NR), stimulation can cause acid secretion increase；
(4) other such as helicobacter pylori infection, Behavioral disturbances.
Current clinically western medical treatment indigestion, more using acid suppression, protection gastric mucosa, promote gastroenteritic power, anti-pylorus spiral shell
The means such as bacillus are treated, and have the effect of certain, but curative effect is of short duration, and long-term use of side effect is more, as Domperidone can influence
Central nervous system, Cisapride may occur in which diarrhoea etc..According to theory of traditional Chinese medical science, indigestion category " gastral cavity ruffian ", " stomachache ", " noisy "
Deng category, its disease is related to the internal organs such as liver and spleen, suitable diagnosis and treatment based on an overall analysis of the illness and the patient's condition gives strengthening the spleen and stomach, dispersing stagnated hepatoqi, promoting digestion, dampness removing in stomach
The methods such as antidiarrheal are treated.
In general, each human mouth has certain smell, and everyone oral cavity smell is not quite similar, most people
The smell that oral cavity distributes is very slight, is not easy to be smelt.But some are due to congenital heredity factor or other external environment factors
(eating habit, pressure big etc.) influences so that oral cavity gives out the special odor of bad news, and specifically, oral cavity produces peculiar smell
The reason for mainly have it is following several：
(1) food residual is fermented in the oral cavity, forms putrefaction, for example the empty and timely cleaning that decays tooth (is not brushed before sleeping
Tooth)；
(2) there are inflammation, such as periodontitis, gingivitis etc., it is necessary to diminish inflammation in time；
(3) oral peculiar smell caused by " stomach heat, stomach fire are prosperous " is, it is necessary to nurse one's health, more difficult elimination comprehensively.
Wherein, from the bacterium colonized in tongue and gingival sulcus, this is to produce oral peculiar smell for the corruption of microorganism in oral cavity
Major reason.By expert's forming by the technology for detection halitosis gas such as gas chromatographic analysis, find this smell by volatilizing
Property sulphur compound (volatile sulphur compounds, VSCs), indoles, methyl indol, amine and aliphatic acid composition, they
The neutrocyte and epithelial cell of mucoitin, level in gingival sulcus fluid, dissolving in microbial fermentation saliva, blood, nasal cavity are broken
Polypeptide in bits.Wherein, volatile sulfur compoundses are the important components for causing halitosis, are mainly decomposed by anaerobic bacteria in food
Sulfur-containing amino acid produce, including hydrogen sulfide (H2S), methyl mercaptan (CH3) and diethyl sulfide (CH SH3SCH3) etc..Bacterioides forsythus
Bacteroid, porphyromonas gingivalis (Porphyromonas gingivalis, P.g), middle Prey irrigate bacterium (Prevotella
Intermedia, P.i), Fusobacterium nucleatum (Fusobacterium nucleatum, F.n) and treponema dentium of dwelling belong to
Grain-negative anaerobic bacteria, can utilize bacterium substrate generation volatile sulfur compoundses, cause smelly bacterium to be suspicious, enter one through modern study
Step screening, porphyromonas gingivalis, middle Prey irrigate bacterium, Fusobacterium nucleatum is known as being a mouthful main bacteria for source property halitosis.
Oral peculiar smell has a strong impact on external image and the social activity of people, allows people to feel to constrain, be melancholy.The World Health Organization will
Halitosis is reported as a kind of disease.Investigation display, Chinese halitosis illness rate are 27.5%.And in western countries, then for
50%.The people that the whole world there are about 10%~65% once suffers from halitosis.The method of conventional cleaning oral peculiar smell mainly has：Keep oral cavity
Sanitation and hygiene, tongue is cleaned in time, gargled with clear water, covered using products such as chewing gums, mouth can not be inherently eliminated
Cavity foreign flavor.
In addition, previously mentioned indigestion is also possible to trigger gastro-intestinal problems, there is the symptom of oral peculiar smell.
In most cases, a certain degree of indigestion can not attract people's attention, although and oral peculiar smell shadow
The daily exchange and life of people is rung, also disease is not treated as and payes attention to, people are even also unwilling medication treatment, for disappearing
Taking for scorching medicine even more has a misgiving.
Therefore, a kind of composition for reaching by conditioning and improving indigestion, suppressing mouth disease is developed and develops, for
The daily health caring of people and clinical application supplement, have very useful meaning.
The content of the invention
The invention provides a kind of composition, is assembled by commonly using the simple of plant material, reaches regulation indigestion, suppression
Oral bacteria processed, the effect for improving oral peculiar smell.
Present invention also offers the preparation method of the composition, and it is obvious, convenient to take that plant material is prepared into curative effect
Preparation.
In order to solve the above technical problems, technical scheme is as follows：
A kind of composition, active ingredient therein come from following plant material combination, and the plant material combination includes
The plant material of following parts by weight：1~10 part of cloves, 1~10 part of Pogostemon cablin.
Further, the mass ratio of cloves and Pogostemon cablin is 1：2~2：1.
Composition disclosed in this invention, it can further include certain auxiliary material.
The auxiliary material is acceptable conventional auxiliary material during food, health products and medicine preparation, such as including routine
Diluent, excipient, filler, adhesive, wetting agent, disintegrant, sorbefacient, surfactant, absorption carrier, profit
Lubrication prescription etc., such as starch, mannitol, antierythrite, xylitol, sorbierite, maltitol, lactose, fructose, sucrose, glucose, micro-
Crystalline cellulose, dextrin, sodium acid carbonate, sodium carbonate, saleratus, potassium carbonate, ammonium hydrogencarbonate, carbonic acid ammonia, tartaric acid, malic acid,
Citric acid, fumaric acid, maleic acid, tartaric acid, butanedioic acid, stevioside, disodium glycyrrhizinate, trisodium glycyrrhetinate, tripotassium glycyrrhetate, arrowroot
Glucin, saccharin, saccharin sodium, sodium cyclohexylsulfamate, L-aspartyl-L-phenylalanine methylester, acesulfame potassium, Sucralose,
One or more in essence and magnesium stearate, other auxiliary materials can also be selected according to real needs.
In specific embodiments of the present invention, the composition can be the decocting liquid of plant material combination through being dried to obtain
Stream cream or dry cream made of extract formulation, now the proportioning of plant material can be converted into crude drug gauge.
Composition provided by the invention, its raw material is common Common materials, and principal component comes from medicinal and edible plant, is come
Source is extensive and security is good, the crowd of needs can be supplied to as food, health products or conditioning sex pill, so to its formulation
It is not specially limited, for example, it may be plant material forms according to prescription compounding, soup is taken after conventionally being decocted
Agent (decocting liquid), from being convenient for carrying and taking consideration, it can use industrialization pharmaceutical technology that plant material is processed into conventional agent
Type, the formulation include but is not limited to paste, granule, tablet, pill, powder, capsule and oral liquid etc. or planted
The preparation that the direct crushing and processing of raw material form.
" stream cream " of the present invention, it is after plant material combination is boiled with decocting, decocting liquid is carried out further dense
The semimobile paste that contracting is dried and makes its solid content be obtained after improving；" dry cream " of the present invention, it is that convection current cream is straight
Capable concentrate drying is tapped into, or is obtained after drying after auxiliary material is added in flowing cream, is substantially properly termed as solids；Institute of the present invention
" dried cream powder " stated, then it is to crush dry cream, obtained powder material.
The present invention also offer said composition is preparing regulation indigestion, is suppressing to cause halitosis bacteria breed, improvement oral cavity different
The application of taste.
The preparation of said composition is used for digestive discomfort, indigestion, or shows oral peculiar smell and halitosis symptom
Ordinary consumer or patient, it can be effectively improved and cure related symptoms.
Present invention also offers a kind of preparation method of above-mentioned composition, mainly comprise the steps of：
The plant material is weighed and mixed according to aforementioned proportion, is boiled with decocting and collects decocting liquid；
The decocting liquid is concentrated at 60~80 DEG C, collects 1.20~1.50g/mL of solid content stream cream；
The stream cream is prepared into pharmaceutical preparation.
Preparation in accordance with the present invention, plant material combination is subjected to appropriate decocting and boiled, decocting liquid is collected, as preparation
The raw material of required preparation, processing is boiled in the decocting of plant material can use normal process steps, i.e. decoct plant material with suitable quantity of water
It is one or many, collect decocting liquid.For example, in a particular embodiment, can be every time using 2~10 times of plant material quality
Decocting is boiled 0.5~3 hour, is decocted more than 2 times, merges decocting liquid.
Further, the water of 3~7 times of plant material quality can be used to be decocted.
Further, it can be 2~3 times to decoct number.
The plant material in the present invention is generally the plant tissue through drying process, and its cell dries up atrophy.Can be with
Understand, if first passing through the immersion of certain time before decoction, medicinal material surface wettability, softening, plant cell expansion can be made,
Therefore, in order to more preferably carry out the extraction of plant material active ingredient, first plant material can be soaked in water before decoction
Bubble, specific soak time is depending on the property of plant material.
In the present invention, before plant material decoction, the good plant material of mixture first can be soaked 0.5~1 in water
Hour.
Before decoction, the good plant material temperature of mixture can be soaked 0.5~1 hour, such as in room temperature or environment temperature
Lower immersion, or appropriate heating immersion (such as room temperature is to about 30 DEG C), beneficial to the leaching for promoting plant material active ingredient.
According to embodiment of the present invention, the decocting liquid for decocting to obtain to plant material is first suitably condensed into stream paste, then
It is further processed into predetermined formulation.
Further, by the stream cream and dextrin or microcrystalline cellulose with 1：5~5：1 mass ratio mixing, and in 50~
Dried at 90 DEG C to moisture and be less than 5%, dried cream powder is made.
Further, the present invention in pharmaceutical composition preparation method, in addition to by the dried cream powder be made including but not
The step of being limited to paste, granule, tablet, pill, powder, capsule etc..According to the characteristics of formulation, can also add appropriate
Additive adjusts taste and mouthfeel, for example, adding appropriate sweet substance, essence etc..Composition provided by the invention can also
Oral liquid formulation is made, i.e. by the stream cream that decocting liquid is concentrated to give according to routine operation, such as add deionized water or injection
Water, and necessary seasoning is carried out, the oral liquid of needs is made.
The invention provides a kind of composition, wherein, the pharmacological action of each plant material is as follows：
Cloves is plant clove of myrtaceae Eugenia caryophyllata Thunb. dry flower, also known as public affairs
Cloves.Property of medicine temperature, acrid flavour.Returns spleen, stomach, lung, kidney channel；Pulvis aromaticus drops；There is the effect of inverse middle benefit gas drop, eliminating cold to stop pain, warming kidney and enhancing yang.
For stomach cold hiccup, vomiting gastric disorder causing nausea, coldness and pain in the epigastrium, dysentery, impotence, Gong Leng, halitosis tooth infantile malnutrition due to digestive disturbances or intestinalparasites.
Pogostemon cablin is labiate Pogostemon cablin Pogostemon cablin (Blanco) Benth. drying overground part
Point.The property of medicine is pungent, tepor.Returns spleen, stomach, lung channel.Eliminate dampness with aromatics and middle preventing or arresting vomiting, deliver the effect of relieving summer-heat, for turbi damp obstructing in middle-JIAO,
The vomiting of gastral cavity ruffian, summer-heat and damp exterior syndrome, damp-warm syndrome from the beginning of, heating burnout, it is uncomfortable in chest do not relax, cold-dampness closes heat, stomachache vomiting and diarrhoea, the disease such as nasosinusitis headache
Disease.Pogostemon cablin decocts water containing gargling, and is festered available for treatment noma, and recent studies is found, Pogostemon cablin can suppress oral cavity bacterium taste
It is raw, there is certain mitigation to oral peculiar smell.
The composition of the present invention is that the plant material of conventional integration of drinking and medicinal herbs is carried out into dialectical compatibility to be formed, and application effect shows
Show, the gastrointestinal function of individual can be improved, reduce and eliminate oral peculiar smell.The effect above should improve peristole speed
With gastric emptying speed, gastric secretion is promoted, adds gastrin, to adjust indigestion, improves gastrointestinal function, and then
Eliminate the oral peculiar smell caused by " stomach heat, stomach fire are prosperous "；Simultaneously by suppressing the bacteria breed for causing oral cavity to produce peculiar smell, regulation
Oral cavity flora balances, and also functions to the effect for reducing and eliminating oral peculiar smell.
Pogostemon cablin is used compared to simple, composition provided by the invention is eliminating oral peculiar smell side by synergy
The effect in face is more obvious.
Composition prescription disclosed by the invention is simple, action effect is obvious, gentle non-stimulated, ordinary consumer and related trouble
Person is easily accepted by；Preparation method of composition disclosed by the invention is simple, is easy to promote on a large scale；Also, due to using relatively conventional
Plant material prepare composition, cost is cheap.
Embodiment
To make the object, technical solutions and advantages of the present invention clearer, below in conjunction with embodiments of the invention and reality
Example is tested, the technical scheme in the embodiment of the present invention is clearly and completely described, it is clear that described embodiment is this hair
Bright part of the embodiment, rather than whole embodiments.Based on the embodiment in the present invention, those of ordinary skill in the art are not having
There is the every other embodiment made and obtained under the premise of creative work, belong to the scope of protection of the invention.
Embodiment 1
400 grams of cloves, 200 grams of Pogostemon cablin are weighed, is added water to cook after mixing 2 times, adds 3000 grams of water and decoction 1 every time
Hour, obtained decocting liquid is merged, filtration, filtrate is concentrated under reduced pressure into about 1.30g/mL at about 70 DEG C, obtains medicine stream cream.
Granule is made in medicine stream cream obtained above, specific method is as follows：
By said medicine stream cream, the microcrystalline cellulose or dextrin of equivalent weight are added, after stirring, is done at about 80 DEG C
It is dry, it is less than 5% to moisture, gets dry extract, crushes, get dry extract powder；
Above-mentioned dried cream powder and the cane sugar powder of 4 times of weight are mixed, add water to pelletize, dries, produces granule.
Embodiment 2
300 grams of cloves, 300 grams of Pogostemon cablin are weighed, is added water to cook after mixing 3 times, adds 4000 grams of water and decoction 1 every time
Hour, obtained decocting liquid is merged, filtration, filtrate is concentrated under reduced pressure into 1.35g/mL or so at about 75 DEG C, obtains medicine stream
Cream.
Tablet is made in medicine stream cream obtained above, specific method is as follows：
Said medicine stream cream is mixed with the dextrin of 0.5 times of quality, after stirring, dries to moisture and contains at about 50 DEG C
Amount is less than 5%, and dry cream is made, and crushes, get dry extract powder.
Above-mentioned dried cream powder and the microcrystalline cellulose of 3 times of weight are mixed, adds water granulation, drying, then adds dry cream silty
The essence and 1% magnesium stearate of amount 1%, tabletting after mixing, produce tablet.
Embodiment 3
400 grams of cloves, 600 grams of Pogostemon cablin are weighed, after mixing, adds 6000 grams of water, soaks 0.5 under room temperature (25 DEG C or so)
Decocted 40 minutes after hour, obtain decocting liquid；Continue to add 6000 grams of water and decoct 40 minutes, decocting liquid will merge twice, and filter, filter
Liquid is concentrated under reduced pressure into about 1.20g/mL at about 80 DEG C, obtains medicine stream cream；
Said medicine stream cream is dried under reduced pressure at about 60 DEG C, crushed, get dry extract powder；
Above-mentioned dried cream powder and the cane sugar powder of 4 times of weight are mixed, produce powder.
Embodiment 4
500 grams of cloves, 400 grams of Pogostemon cablin are weighed, 2700 grams of water are added after mixing, are soaked at a temperature of 30 DEG C or so
Decocted 1 hour after 0.5 hour, obtain decocting liquid；The step 2 time for adding 2700 grams of water and decocting 1 hour is repeated, by obtain 3 water
Decocting liquid merges, and filtration, filtrate is concentrated under reduced pressure into 1.20g/mL at about 70 DEG C, obtains medicine stream cream.
Above-mentioned stream cream is mixed with the deionized water of 5 times of weight, appropriate amount of essence, Sucralose is added, produces oral liquid.
Influence of the experimental example 1 to Mice with Spleen model
Upper digestive tract dyskinesia is dyspeptic dominant pathophysiology basis, and this experiment causes to move using rhubarb
Thing model of spleen deficiency, illustrate that the present composition treats dyspeptic effect.
Experimental animal：Healthy kunming mice, totally 50, male and female half and half, 25 ± 2g of body weight, can voluntarily feeding, and have abundance
Fresh tap water, its feeding environment meets SPF experimental animal level environmental facility standards.
Experimental drug：The dried cream powder being prepared in embodiment 3.
Experimental program：
Take above-mentioned kunming mice, be divided into 5 groups at random, i.e., blank control group, model of spleen deficiency control group, low dose group, in
Dosage group, high dose group.
In addition to blank control group, remaining 4 groups are administered with 0.5g/mL rhubarbs decocting liquid by 40mL/kg weights ig, often
Day 1 time, continuous 10 days, cause model of spleen deficiency；It is the same that blank control group such as gives at capacity distilled water, administration number of times and the time.
Low dose group, middle dose group, high dose group are distinguished into gastric infusion according to dosage ig shown in table 1, i.e., in embodiment 3
The dried cream powder being prepared, once a day, continuous 7 days；Blank control group and insufficiency of the spleen control group such as give at the capacity distilled water, administration
Number and time are the same.
Water is can't help in mouse fasting after last dose, and 0.1% methyl orange solution is given by 0.2mL/ ig after being administered 2 hours,
Dislocate and put to death after 15 minutes, cut open the belly and win stomach, be placed in small beaker, add distilled water 10mL, split gastric content is abundant after stomach
Wash in distilled water, after adjusting pH value to be centrifuged 20 minutes to 6.0~6.5,3500r/min with 5% sodium bicarbonate solution, utilize light splitting
Photometer, the colorimetric at absorbing wavelength 420nm, is returned to zero with distilled water, the absorption photometric value of residual methyl orange in detection stomach, as
Residual quantity, its calculation formula are：Methyl orange residual rate=(methyl orange absorption photometric value/benchmark methyl orange absorption photometric value in stomach)
× 100%, benchmark methyl orange absorption photometric value is the absorption photometric value of 0.1% methyl orange solution in this experimental program.
Data statistics uses SPSS softwares, carries out t inspections to each group of data, data are represented with x ± s, the results are shown in Table 1.
The composition of table 1 causes the influence (x ± s, n=10) of mice with spleen deficiency gastric emptying to rheum officinale
| Group | Dosage (g/kg) | Absorption photometric value | Methyl orange residual rate (%) |
| Blank control group | — | 0.210±0.041 | 47.22±7.34 |
| Model of spleen deficiency control group | — | 0.308±0.055 | 69.82±10.58 |
| Low dose group | 0.41 | 0.235±0.045 | 54.78±7.64 |
| Middle dose group | 0.82 | 0.229±0.042 | 52.95±8.54 |
| High dose group | 1.64 | 0.218±0.061 | 48.14±5.78 |
The result of table 1 shows, the continuous 10 days model of spleen deficiency control groups for giving rhubarb decocting liquid, and methyl orange residual rate is bright
It is aobvious to be higher than blank control group, illustrate that rhubarb decocting liquid energy substantially suppresses mouse gastric emptying；Model of spleen deficiency control group and blank pair
Compared according to group, P<0.05, there is notable significant difference.Therefore, rhubarb decocting liquid causes Mice with Spleen model to be successfully established.
After being administered one week, low dose group, middle dose group, the methyl orange residual rate of high dose group are significantly lower than model of spleen deficiency pair
According to group；Also, as dosage increases, methyl orange residual rate reduces, the methyl orange of high dose group and blank control group remains
Rate is very close.Therefore, composition of the invention can improve peristole speed and gastric emptying speed, treat indigestion disease
It is curative for effect.
Influence of the experimental example 2 to rat gastric secretion
Gastroxia is dyspeptic dominant pathophysiology basis, and this experiment is by the present composition to stomach
Liquid secretion, the influence of hydrochloric acid in gastric juice discharge, illustrate that it treats dyspeptic effect.
Experimental animal：Healthy SD rat, totally 40, male and female half and half, can voluntarily feeding, and have abundance fresh tap water,
Its feeding environment meets SPF experimental animal level environmental facility standards.
Experimental drug：The dried cream powder being prepared in embodiment 3.
Experimental program：
Above-mentioned SD rats are taken to be divided into 4 groups, respectively blank control group, low dose group, middle dose group, high dose at random
Group.
Low dose group, middle dose group, high dose group are distinguished into gastric infusion according to dosage ig shown in table 2, i.e., in embodiment 3
The dried cream powder being prepared, by daily single, continuous 7 days；Blank control group such as gives at the capacity distilled water, administration number of times and when
Between it is the same.SD Rat Fasts can't help water 24 hours after last dose, row pyloric ligation after animal was anesthetized with ether on 1,
In duodenal administration 1 time, suturing them otch, wound is covered, after 3 hours, fu jie of taking out stitches out pricks orifice of the stomach and takes stomach, pours out in stomach
It is tolerant, gastric juice total amount is recorded after centrifugation.
Aspirate supernatant 2mL, add distilled water 20mL, add phenolic red indicator 2 to drip, with 20mmol/L NaOH solutions and dripping
It is fixed, NaOH solution consumption is recorded, calculates total acidity and total acid output.
Data statistics uses SPSS softwares, carries out t inspections to each group of data, data are represented with x ± s, the results are shown in Table 2.
Influence (x ± s, n=10) of the composition of table 2 to rat gastric secretion
Through statistical analysis, low dose group, middle dose group, high dose group are compared with blank control group in table 2, P<0.05.
As a result show, continuous 7 days low dose groups being administered, middle dose group, high dose groups are compared with blank control group, gastric juice
Secretory volume, total acidity gastric juice and total acid output significantly improve, and as dosage increases, the effect above is more obvious.Therefore,
The composition of the present invention can be obviously promoted rat gastric secretion, increase gastrin, show for dyspeptic therapeutic effect
Write.
Experimental example 3 causes the experiment of the inhibitory action of smelly bacterium to oral cavity
Porphyromonas gingivalis (P.g), middle Prey irrigate bacterium (P.i), Fusobacterium nucleatum (F.n) is known as being a mouthful source property mouth
Smelly main bacteria, by the experiment of the inhibitory action to above-mentioned bacterium, illustrating the composition of the present invention prevents oral peculiar smell
Effect.
(1) experimental strain (offer of Tianjin University Of Traditional Chinese Medicine's pharmacological evaluation room)
Porphyromonas gingivalis (P.g)：ATCC 33277；
Middle Prey irrigates bacterium (P.i)：ATCC 25611；
Fusobacterium nucleatum (F.n)：ATCC 17953.
(2) culture medium
Brain heart infusion broth (BHI), blood agar basis (Oxoid, Britain), and add Hem in-VitK1 liquid, TPY liquid
Culture.
(3) prepared by bacterium solution
Bacterium freezes strain after recovering, increasing bacterium, morphological examination and biochemical identification and be pure culture, and pure liquid (pH is buffered using PBS
It is worth 7.2) to prepare bacterial suspension (1.0 × 106Cfu/mL), it is standby.
(4) preparation of composition
The medicine stream cream being prepared in Example 4, it is diluted with water to the combination that conversion raw medicinal herbs concentration is 2.4g/mL
Thing.
(5) preparation of Radix agastaches extract
120 grams of Pogostemon cablin is taken, adds 360 grams of water and is decocted 1 hour after soaking 0.5 hour at a temperature of 30 DEG C or so, obtained
Decocting liquid；The step 2 time for adding 360 grams of water and decocting 1 hour is repeated, obtain 3 decocting liquids are merged, filtration, filtrate is about
1.20g/mL is concentrated under reduced pressure at 70 DEG C, obtains the medicine stream cream of Pogostemon cablin；
The medicine stream cream of above-mentioned Pogostemon cablin is centrifuged into removal of impurities, it is the wide of 2.4g/mL to be diluted with water to conversion raw medicinal herbs concentration
Agastache extract.
(6) composition is to experimental strain minimum inhibitory concentration (MIC)
With pipettor by above-mentioned composition, Radix agastaches extract by being dissolved in TPY fluid nutrient mediums respectively with double dilution method
In, its ultimate density (conversion raw medicinal herbs concentration) is reached 2.4g/mL, 1.2g/mL, 0.6g/mL, 0.3g/mL；Containing above-mentioned group
Equivalent experiment bacteria suspension is added in the TPY fluid nutrient mediums of compound；The another nutrient solution set without above-mentioned composition is as positive right
According to the nutrient solution without above-mentioned composition and bacterium is as negative control.Concussion, 37 DEG C of anaerobism (N2：800mL/L, H2：10mL/
L, CO2：100mL/L) cultivate 48 hours.To visually observe bacterium without growth, the lowest combined thing of bacterial growth is had no under light microscopic
Concentration or Radix agastaches extract concentration are its MIC value.The measure of each bacterial strain is repeated 3 times, and takes MIC averages, experimental result ginseng
It is shown in Table 3 and table 4.
The oral cavity of table 3 causes the inhibitory action contrast of smelly bacterium
The result of table 3 shows that each test strain is equal in negative control group (nutrient solution without above-mentioned composition and bacterium)
Without bacterial growth；Each test strain has bacterial growth in positive controls (nutrient solution for being free of above-mentioned composition)；Pogostemon cablin
P.g has bacterial growth in 0.3g/mL concentration in extract group, and P.i has bacterial growth, F.n in 0.3g/mL, 0.6g/mL
There is bacterial growth in 0.3g/mL concentration；Without bacterial growth in composition group.
It is as shown in table 4 to calculate Radix agastaches extract, the MIC value of composition：
The MIC value of the composition of table 4 and Radix agastaches extract
| Bacterium | Radix agastaches extract (g/mL) | Composition (g/mL) |
| P.g | 0.6 | 0.3 |
| P.i | 1.2 | 0.3 |
| F.n | 0.6 | 0.3 |
The result of table 4 shows that composition of the invention is to all experimental bacterias：Porphyromonas gingivalis (P.g), middle Prey
Fertile bacterium (P.i), Fusobacterium nucleatum (F.n) have inhibitory action, and shown through statistical analysis, composition of the invention it is antibacterial
Effect is better than alone Radix agastaches extract.
Finally it should be noted that：Various embodiments above is merely illustrative of the technical solution of the present invention, rather than its limitations；To the greatest extent
The present invention is described in detail with reference to foregoing embodiments for pipe, it will be understood by those within the art that：Its according to
The technical scheme described in foregoing embodiments can so be modified, either which part or all technical characteristic are entered
Row equivalent substitution；And these modifications or replacement, the essence of appropriate technical solution is departed from various embodiments of the present invention technology
The scope of scheme.
Claims (10)
1. a kind of composition, active ingredient therein combines from following plant material, and plant material combination is comprising such as
The plant material of lower parts by weight：1~10 part of cloves, 1~10 part of Pogostemon cablin.
2. composition according to claim 1, it also includes acceptable auxiliary material in prepared by food, health products and medicine.
3. the mass ratio of composition according to claim 1 or 2, wherein cloves and Pogostemon cablin is 1：2~2：1.
4. according to the composition described in claim any one of 1-3, it is the decocting liquid of plant material combination through being dried to obtain
Flow preparation made of cream or dry cream.
5. composition according to claim 4, wherein, the preparation is paste, granule, tablet, oral liquid or capsule
Agent.
6. the composition described in claim any one of 1-5 is preparing regulation indigestion, improves oral peculiar smell or is suppressing cause mouth
Purposes in the food of smelly bacteria breed, health products or medicine.
7. the preparation method of the composition described in claim any one of 1-5, comprises the following steps：
The plant material is weighed and mixed in proportion, is boiled with decocting and collects decocting liquid；
The decocting liquid is concentrated under reduced pressure in 60~80 DEG C, collects 1.20~1.50g/mL of solid content stream cream；
The stream cream is prepared into preparation.
8. preparation method according to claim 7, wherein, the decocting of 2~10 times of plant material combination quality is used every time
Boil 0.5~3 hour, decoct more than 2 times, merge decocting liquid.
9. the preparation method according to claim 7 or 8, wherein, by the stream cream with dextrin or microcrystalline cellulose with quality
Than 1：5~5：1 mixing, and dried at 50~90 DEG C to moisture and be less than 5%, dried cream powder is made.
10. preparation method according to claim 9, wherein, in addition to paste, granule, piece is made in the dried cream powder
The step of agent or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610877072.3A CN107875197A (en) | 2016-09-30 | 2016-09-30 | A kind of composition and its production and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610877072.3A CN107875197A (en) | 2016-09-30 | 2016-09-30 | A kind of composition and its production and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107875197A true CN107875197A (en) | 2018-04-06 |
Family
ID=61768932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610877072.3A Pending CN107875197A (en) | 2016-09-30 | 2016-09-30 | A kind of composition and its production and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107875197A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4544551A (en) * | 1976-11-30 | 1985-10-01 | Hong Yue Du | Antipeptic ulcer composition |
| CN102526427A (en) * | 2012-02-20 | 2012-07-04 | 广西梧州三鹤药业有限公司 | Chinese medicinal composition for treating gastrointestinal diseases and quality inspection method |
-
2016
- 2016-09-30 CN CN201610877072.3A patent/CN107875197A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4544551A (en) * | 1976-11-30 | 1985-10-01 | Hong Yue Du | Antipeptic ulcer composition |
| CN102526427A (en) * | 2012-02-20 | 2012-07-04 | 广西梧州三鹤药业有限公司 | Chinese medicinal composition for treating gastrointestinal diseases and quality inspection method |
Non-Patent Citations (2)
| Title |
|---|
| 北京医学院药学系: "《 中草药学讲义 下》", 31 March 1979 * |
| 阚成国主编: "《家庭营养保健全典》", 31 May 2007, 哈尔滨出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102511869B (en) | Thickened red jujube ginger pulp | |
| CN103906526A (en) | Wrap fermentation method using medicinal flower, and composition for external application onto the skin using same | |
| KR20110129673A (en) | Herbal composition for removing hangover and beverage containing the same | |
| CN103520578A (en) | Traditional Chinese medicine composition for treating oral ulcer and preparation method thereof | |
| KR20150040392A (en) | undiluted stevia liquid and the berages, and its manufacturing method | |
| KR102341885B1 (en) | A natural tea removing the effect of hangover contained the extract material in Hovenia dulcis and a cactus | |
| CN104247913A (en) | Health rice vermicelli | |
| CN105851740A (en) | Health-care beverage capable of invigorating stomach and promoting digestion and making method thereof | |
| KR101771090B1 (en) | Composition for body temperature rise with medicinal herbs classified as a food ingredient and Manufacturing method thereof | |
| CN108813501B (en) | Health-preserving honey paste with functions of clearing heat, moistening lung, relieving cough, reducing phlegm, relieving asthma and regulating human body functions | |
| CN106235318A (en) | The method preparing ferment for primary raw material with Flos Lonicerae, Rhizoma Curcumae Longae | |
| AU654365B2 (en) | Stevia extract-containing liquid internal medicine and method of preparing the same | |
| KR20130122834A (en) | Korean herb tea composing of extract from spring onion root and method preparing thereof | |
| CN108635461A (en) | Dry eyes atomized liquid | |
| KR20120058672A (en) | Korean Herb Tea composing of extract from Spring onion root and Method preparing thereof | |
| KR100506622B1 (en) | Healthy food composition and method for producing the same | |
| CN101254263A (en) | Compound Japanese polygala oral liquid and method of preparing the same | |
| KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
| KR101512230B1 (en) | Arthritis Remedy Composition and manufacture method having immunity and the circulation of the blood improvement fuction | |
| CN110214902A (en) | A kind of children's correction partial eclipse type selenium-rich complete nourishing powder | |
| CN109223886A (en) | Chinese medicine composition and its preparation method and application for invigorating the spleen to arrest diarrhea | |
| CN106860814B (en) | Health food composition for improving female frequent micturition and urinary incontinence and preparation method and application thereof | |
| CN108419869A (en) | Fiery composition, beverage and preparation method thereof under a kind of heat-clearing toxin expelling | |
| CN107970368A (en) | A kind of houttuynia oral administration liquid for helping to give up smoking and preparation method thereof | |
| CN106259077A (en) | A kind of ecological cultivation method of astacus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180406 |